Home / News

2026-04-28: Keythera Announces Positive Phase 2a Data for KF-0210, an Oral E...

KF-0210 achieved up to ~86.7% reduction in WOMAC pain scores at Week 3, with rapid onset observed as early as Day 8...

2021-04-22

Keythera completed the first administration to a patient in China for its first-in-class investigational drug, KF-0210

KF-0210, developed independently by Keythera Biopharmaceuticals, is a small molecular drug designed to combat tumors by regulating the tumor immune microenvironment and enhancing the body's anti-tumor immune response...

More >>

2021-03-22

Keythera announced the completion of the first patient first dosing in Phase I clinical trial of KF-0210 and secured a Series A+ investment of 100 million RMB

Keythera (Suzhou) Biopharmaceuticals Co., Ltd. (referred to as "Keythera"), an innovative drug development company, announced the administration of the first patient in the Phase I clinical trial of KF-0210 (NCT04713891) in Australia. ...

More >>

2020-12-10

Keythera won New Bud Award 2020 Venture Top 50

After 8-month evaluation, the 2020 Venture Top 50 list was finally unveiled. Richland Equities series enterprise Keythera Biopharmaceuticals won the honor on the top 50 New Bud List!...

More >>

2020-09-28

Keythera completed RMB 100M Series A financing

Recently, Keythera (Suzhou) Biopharmaceutical Co., Ltd., an innovative drug research and development enterprise, announced the completion of a Series A financing of nearly RMB 100 million....

More >>